Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis

Journal of Controlled Release

Volumn 197, Issue , 2015, Pages 190-198

  Arias, José L ^a   Unciti Broceta, Juan D ^b,c   Maceira, José ^b,c   Del Castillo, Teresa ^b,c   Hernández Quero, José ^b   Magez, Stefan ^d   Soriano, Miguel ^b,e   García Salcedo, José A ^b,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF ALMERÍA   (Spain)

Author keywords

African trypanosomiasis; Human; Nanobody nanoparticles conjugation; PEGylation; PLGA; Polymeric nanoparticles; Specific cell targeting

Indexed keywords

ANTIBODIES; CONTROLLED DRUG DELIVERY; DISEASE CONTROL; DISEASES; MAMMALS; MOLECULAR BIOLOGY; NANOPARTICLES;

AFRICAN TRYPANOSOMIASIS; CELL TARGETING; HUMAN; NANOBODY; PEGYLATION; PLGA; POLYMERIC NANOPARTICLES;

TARGETED DRUG DELIVERY;

NANOBODY; NANOPARTICLE; PENTAMIDINE; POLY(DEXTRO LEVO LACTIDE CO GLYCOLIDE ACID)NANOPARTICLE; POLYGLACTIN; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; DRUG CARRIER; EPITOPE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; IC50; IN VITRO STUDY; NONHUMAN; TRYPANOSOMA BRUCEI; TRYPANOSOMA GAMBIENSE; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

ANIMALS; DRUG CARRIERS; ENDOCYTOSIS; EPITOPES; FEMALE; LACTIC ACID; MICE, INBRED C57BL; NANOPARTICLES; PENTAMIDINE; POLYGLYCOLIC ACID; SINGLE-DOMAIN ANTIBODIES; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 84912095638     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.11.002     Document Type: Article

References (62)

1. M.P. Barrett, R.J. Burchmore, A. Stich, J.O. Lazzari, A.C. Frasch, J.J. Cazzulo, and S. Krishna The trypanosomiases Lancet 362 2003 1469 1480
2. R. Brun, and J. Blum Human African trypanosomiasis Infect. Dis. Clin. N. Am. 26 2012 261 273
3. R. Brun, J. Blum, F. Chappuis, and C. Burri Human African trypanosomiasis Lancet 375 2010 148 159
4. M.P. Barrett The fall and rise of sleeping sickness Lancet 353 1999 1113 1114
5. M.P. Barrett The rise and fall of sleeping sickness Lancet 367 2006 1377 1378
6. D. Horn, and R. McCulloch Molecular mechanisms underlying the control of antigenic variation in African trypanosomes Curr. Opin. Microbiol. 13 2010 700 705
7. G. Rudenko African trypanosomes: the genome and adaptations for immune evasion Essays Biochem. 51 2011 47 62
8. P. Overath, and M. Engstler Endocytosis, membrane recycling and sorting of GPI-anchored proteins: Trypanosoma brucei as a model system Mol. Microbiol. 53 2004 735 744
9. C. O'Beirne, C.M. Lowry, and H.P. Voorheis Both IgM and IgG anti-VSG antibodies initiate a cycle of aggregation-disaggregation of bloodstream forms of Trypanosoma brucei without damage to the parasite Mol. Biochem. Parasitol. 91 1998 165 193
10. M. Engstler, T. Pfohl, S. Herminghaus, M. Boshart, G. Wiegertjes, N. Heddergott, and P. Overath Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes Cell 131 2007 505 515
11. D. Salmon, M. Geuskens, F. Hanocq, J. Hanocq-Quertier, D. Nolan, L. Ruben, and E. Pays A novel heterodimeric transferrin receptor encoded by a pair of VSG expression site-associated genes in T. brucei Cell 78 1994 75 86
12. D. Steverding, Y.D. Stierhof, H. Fuchs, R. Tauber, and P. Overath Transferrin-binding protein complex is the receptor for transferrin uptake in Trypanosoma brucei J. Cell Biol. 131 1995 1173 1182
13. A. Luscher, H.P. de Koning, and P. Maser Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting Curr. Pharm. Des. 13 2007 555 567
14. J. Garcia-Salcedo, J. Munday, J. Unciti-Broceta, and H. Koning Progress towards new treatments for human African trypanosomiasis S. Magez, M. Radwanska, Trypanosomes and Trypanosomiasis 2014 Springer Vienna 217 238
15. O. Kayser, C. Olbrich, S.L. Croft, and A.F. Kiderlen Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs Parasitol. Res. 90 Suppl. 2 2003 S63 S70
16. S.M. Moghimi, D. Peer, and R. Langer Reshaping the future of nanopharmaceuticals: ad iudicium ACS Nano 5 2011 8454 8458
17. S. Mitragotri, and J. Lahann Materials for drug delivery: innovative solutions to address complex biological hurdles Adv. Mater. 24 2012 3717 3723
18. A. Beletsi, Z. Panagi, and K. Avgoustakis Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers Int. J. Pharm. 298 2005 233 241
19. T. Betancourt, J.D. Byrne, N. Sunaryo, S.W. Crowder, M. Kadapakkam, S. Patel, S. Casciato, and L. Brannon-Peppas PEGylation strategies for active targeting of PLA/PLGA nanoparticles J. Biomed. Mater. Res. A 91 2009 263 276
20. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Préat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2012 505 522
21. J.P. Bertram, S.M. Jay, S.R. Hynes, R. Robinson, J.M. Criscione, and E.B. Lavik Functionalized poly(lactic-co-glycolic acid) enhances drug delivery and provides chemical moieties for surface engineering while preserving biocompatibility Acta Biomater. 5 2009 2860 2871
22. S. Fredenberg, M. Wahlgren, M. Reslow, and A. Axelsson The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review Int. J. Pharm. 415 2011 34 52
23. D. Klose, F. Siepmann, K. Elkharraz, and J. Siepmann PLGA-based drug delivery systems: importance of the type of drug and device geometry Int. J. Pharm. 354 2008 95 103
24. V.K. Nguyen, A. Desmyter, and S. Muyldermans Functional heavy-chain antibodies in Camelidae Adv. Immunol. 79 2001 261 296
25. S. Muyldermans, C. Cambillau, and L. Wyns Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains Trends Biochem. Sci. 26 2001 230 235
26. K. Els Conrath, M. Lauwereys, L. Wyns, and S. Muyldermans Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs J. Biol. Chem. 276 2001 7346 7350
27. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, and R. Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
28. V.K. Nguyen, R. Hamers, L. Wyns, and S. Muyldermans Loss of splice consensus signal is responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-chain antibodies Mol. Immunol. 36 1999 515 524
29. K.B. Vu, M.A. Ghahroudi, L. Wyns, and S. Muyldermans Comparison of llama VH sequences from conventional and heavy chain antibodies Mol. Immunol. 34 1997 1121 1131
30. S. Muyldermans, T. Atarhouch, J. Saldanha, J.A. Barbosa, and R. Hamers Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains Protein Eng. 7 1994 1129 1135
31. J.D. Unciti-Broceta, T. Del Castillo, M. Soriano, S. Magez, and J.A. Garcia-Salcedo Novel therapy based on camelid nanobodies Ther. Deliv. 4 2013 1321 1336
32. P. Vanlandschoot, C. Stortelers, E. Beirnaert, L.I. Ibanez, B. Schepens, E. Depla, and X. Saelens Nanobodies(R): new ammunition to battle viruses Antivir. Res. 92 2011 389 407
33. S. Oliveira, R.M. Schiffelers, J. van der Veeken, R. van der Meel, R. Vongpromek, P.M. van Bergen En Henegouwen, G. Storm, and R.C. Roovers Downregulation of EGFR by a novel multivalent nanobody-liposome platform J. Control. Release 145 2010 165 175
34. T.N. Baral, S. Magez, B. Stijlemans, K. Conrath, B. Vanhollebeke, E. Pays, S. Muyldermans, and P. De Baetselier Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor Nat. Med. 12 2006 580 584
35. A. Järviluoma, T. Strandin, S. Lülf, J. Bouchet, A.R. Mäkelä, M. Geyer, S. Benichou, and K. Saksela High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain PLoS One 7 2012 e40331
36. M. Behdani, S. Zeinali, M. Karimipour, H. Khanahmad, S. Schoonooghe, A. Aslemarz, N. Seyed, R. Moazami-Godarzi, F. Baniahmad, M. Habibi-Anbouhi, G. Hassanzadeh-Ghassabeh, and S. Muyldermans Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth N. Biotechnol. 30 2013 205 209
37. B. Van De Broek, N. Devoogdt, A. Dhollander, H.L. Gijs, K. Jans, L. Lagae, S. Muyldermans, G. Maes, and G. Borghs Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy ACS Nano 5 2011 4319 4328
38. R. van der Meel, S. Oliveira, I. Altintas, R. Haselberg, J. van der Veeken, R.C. Roovers, P.M. van Bergen en Henegouwen, G. Storm, W.E. Hennink, R.M. Schiffelers, and R.J. Kok Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment J. Control. Release 159 2012 281 289
39. I. Altintas, R. Heukers, R. van der Meel, M. Lacombe, M. Amidi, P.M.P. van Bergen en Henegouwen, W.E. Hennink, R.M. Schiffelers, and R.J. Kok Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells J. Control. Release 165 2013 110 118
40. D. Smolarek, C. Hattab, G. Hassanzadeh-Ghassabeh, S. Cochet, C. Gutierrez, A.G. de Brevern, R. Udomsangpetch, J. Picot, M. Grodecka, K. Wasniowska, S. Muyldermans, Y. Colin, C. Le Van Kim, M. Czerwinski, and O. Bertrand A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines Cell. Mol. Life Sci. 67 2010 3371 3387
41. B. Stijlemans, K. Conrath, V. Cortez-Retamozo, H. Van Xong, L. Wyns, P. Senter, H. Revets, P. De Baetselier, S. Muyldermans, and S. Magez Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm J. Biol. Chem 279 2004 1256 1261
42. K.E. Conrath, M. Lauwereys, M. Galleni, A. Matagne, J.M. Frere, J. Kinne, L. Wyns, and S. Muyldermans Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae Antimicrob. Agents Chemother. 45 2001 2807 2812
43. R.A. Jain The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices Biomaterials. 21 2000 2475 2490
44. M.J. Cózar-Bernal, M.A. Holgado, J.L. Arias, I. Muñoz-Rubio, L. Martín-Banderas, J. Álvarez-Fuentes, and M. Fernández-Arévalo Insulin-loaded PLGA microparticles: flow focusing versus double emulsion/solvent evaporation J. Microencapsul. 28 2011 430 441
45. B. Pérez-Artacho, V. Gallardo, M.A. Ruiz, M.A. Ruiz, and J. Arias Maghemite/poly(d,l-lactide-co-glycolyde) composite nanoplatform for therapeutic applications J. Nanopart. Res. 14 2012 1 10
46. J.D. Unciti-Broceta, J. Maceira, S. Morales, A. Garcia-Perez, M.E. Munoz-Torres, and J.A. Garcia-Salcedo Nicotinamide inhibits the lysosomal cathepsin B-like protease and kills African trypanosomes J. Biol. Chem. 288 2013 10548 10557
47. D.P. Nolan, M. Geuskens, and E. Pays N-linked glycans containing linear poly-N-acetyllactosamine as sorting signals in endocytosis in Trypanosoma brucei Curr. Biol. 9 1999 1169 1172
48. M.C. Field, and M. Carrington The trypanosome flagellar pocket Nat. Rev. Microbiol 7 2009 775 786
49. Q. Sun, M. Radosz, and Y. Shen Challenges in design of translational nanocarriers J. Control. Release 164 2012 156 169
50. R. Gref, A. Domb, P. Quellec, T. Blunk, R.H. Müller, J.M. Verbavatz, and R. Langer The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres Adv. Drug Deliv. Rev. 64 Supplement 2012 316 326
51. M.A. Ibrahim, A. Ismail, M.I. Fetouh, and A. Göpferich Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres J. Controlled Rel. 106 2005 241 252
52. M.A. Holgado, J. Álvarez-Fuentes, M. Fernández-Arévalo, and J.L. Arias Possibilities of Poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer Curr. Drug Targets 12 2011 1096 1111
53. L. Martín-Banderas, E. Sáez-Fernández, M.Á. Holgado, M.M. Durán-Lobato, J.C. Prados, C. Melguizo, and J.L. Arias Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing® for efficient antitumor activity Int. J. Pharm. 443 2013 103 109
54. M.A. Holgado, J.L. Arias, M.J. Cózar, J. Alvarez-Fuentes, A.M. Gañán-Calvo, and M. Fernández-Arévalo Synthesis of lidocaine-loaded PLGA microparticles by flow focusing: Effects on drug loading and release properties Int. J. Pharm. 358 2008 27 35
55. G. Mittal, D.K. Sahana, V. Bhardwaj, and M.N.V. Ravi Kumar Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo J. Controlled Rel. 119 2007 77 85
56. S. Costa Lima, V. Rodrigues, J. Garrido, F. Borges, P. Kong Thoo Lin, and A. Cordeiro da Silva In vitro evaluation of bisnaphthalimidopropyl derivatives loaded into pegylated nanoparticles against Leishmania infantum protozoa Int. J. Antimicrob. Agents. 39 2012 424 430
57. H. Van de Ven, M. Vermeersch, A. Matheeussen, J. Vandervoort, W. Weyenberg, S. Apers, P. Cos, L. Maes, and A. Ludwig PLGA nanoparticles loaded with the antileishmanial saponin β-aescin: Factor influence study and in vitro efficacy evaluation Int. J. Pharm. 420 2011 122 132
58. E.L. Romero, and M.J. Morilla Nanotechnological approaches against Chagas disease Adv. Drug Deliv. Rev. 62 2010 576 588
59. N.S. Santos-Magalhães, and V.C.F. Mosqueira Nanotechnology applied to the treatment of malaria Adv. Drug Deliv. Rev. 62 2010 560 575
60. J.K. Thuita, S.M. Karanja, T. Wenzler, R.E. Mdachi, J.M. Ngotho, J.M. Kagira, R. Tidwell, and R. Brun Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis Acta Trop. 108 2008 6 10
61. J.A. Frearson, S. Brand, S.P. McElroy, L.A. Cleghorn, O. Smid, L. Stojanovski, H.P. Price, M.L. Guther, L.S. Torrie, D.A. Robinson, I. Hallyburton, C.P. Mpamhanga, J.A. Brannigan, A.J. Wilkinson, M. Hodgkinson, R. Hui, W. Qiu, O.G. Raimi, D.M. van Aalten, R. Brenk, I.H. Gilbert, K.D. Read, A.H. Fairlamb, M.A. Ferguson, D.F. Smith, and P.G. Wyatt N-myristoyltransferase inhibitors as new leads to treat sleeping sickness Nature 464 2010 728 732
62. D. Damper, and C.L. Patton Pentamidine transport and sensitivity in brucei-group trypanosomes J. Protozool. 23 1976 349 356